[go: up one dir, main page]

ATE424848T1 - Pharmazeutische zusammensetzungen für die kontrollierte freigabe von biologischen wirkstoffen - Google Patents

Pharmazeutische zusammensetzungen für die kontrollierte freigabe von biologischen wirkstoffen

Info

Publication number
ATE424848T1
ATE424848T1 AT05807464T AT05807464T ATE424848T1 AT E424848 T1 ATE424848 T1 AT E424848T1 AT 05807464 T AT05807464 T AT 05807464T AT 05807464 T AT05807464 T AT 05807464T AT E424848 T1 ATE424848 T1 AT E424848T1
Authority
AT
Austria
Prior art keywords
biologically active
controlled release
methods
provides
pharmaceutical compositions
Prior art date
Application number
AT05807464T
Other languages
English (en)
Inventor
Li Yuhua
Benjamin Chien
Original Assignee
Quest Pharmaceutical Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quest Pharmaceutical Services filed Critical Quest Pharmaceutical Services
Application granted granted Critical
Publication of ATE424848T1 publication Critical patent/ATE424848T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT05807464T 2004-08-12 2005-08-11 Pharmazeutische zusammensetzungen für die kontrollierte freigabe von biologischen wirkstoffen ATE424848T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60090704P 2004-08-12 2004-08-12

Publications (1)

Publication Number Publication Date
ATE424848T1 true ATE424848T1 (de) 2009-03-15

Family

ID=35839986

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05807464T ATE424848T1 (de) 2004-08-12 2005-08-11 Pharmazeutische zusammensetzungen für die kontrollierte freigabe von biologischen wirkstoffen

Country Status (21)

Country Link
US (1) US7964219B2 (de)
EP (1) EP1786400B1 (de)
JP (1) JP5053846B2 (de)
KR (1) KR101231856B1 (de)
CN (1) CN101035512B (de)
AT (1) ATE424848T1 (de)
AU (1) AU2005271242B9 (de)
BR (1) BRPI0514297A (de)
CA (1) CA2576689C (de)
CY (1) CY1109425T1 (de)
DE (1) DE602005013244D1 (de)
DK (1) DK1786400T3 (de)
ES (1) ES2323141T3 (de)
HK (1) HK1108638A1 (de)
MX (1) MX2007001760A (de)
NZ (1) NZ553149A (de)
PL (1) PL1786400T3 (de)
PT (1) PT1786400E (de)
RU (1) RU2390355C2 (de)
SI (1) SI1786400T1 (de)
WO (1) WO2006017852A2 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1786400B1 (de) * 2004-08-12 2009-03-11 Quest Pharmaceutical Services Pharmazeutische zusammensetzungen für die kontrollierte freigabe von biologischen wirkstoffen
ITRM20050344A1 (it) * 2005-06-30 2007-01-01 Luca Maria De Sali o complessi di sostanze metil-donatrici con acido fitico o suoi derivati e relativo metodo di sintesi.
HUE045165T2 (hu) 2005-08-19 2019-12-30 Amylin Pharmaceuticals Llc Exendin diabetes kezelésére és testtömeg csökkentésére
EP2359809B1 (de) * 2005-12-22 2019-08-14 Novartis AG Zusammensetzung mit verzögerter Freisetzung enthaltend octreotide und zwei oder mehr polylactide-co-glycolide polymere
KR20150017777A (ko) * 2006-01-18 2015-02-17 포시에이서 파마슈티컬스 인코포레이티드 안정성이 강화된 약학 조성물
WO2007147902A2 (en) 2006-06-22 2007-12-27 Biocompatibles Uk Limited Rehydratable pharmaceutical product
EP1917971A1 (de) * 2006-10-27 2008-05-07 Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) Zusammensetzungen mit verlängerter Wirkstofffreigabe, enthaltend Polymere mit sehr niedrigem Molekulargewicht
KR100805208B1 (ko) * 2007-03-27 2008-02-21 주식회사 펩트론 엑센딘 함유 서방성 제제 조성물, 엑센딘 함유 서방성미립구 및 이의 제조 방법
PL2157967T3 (pl) * 2007-04-23 2013-06-28 Intarcia Therapeutics Inc Formulacje zawiesinowe peptydów insulinotropowych i ich zastosowania
WO2009033711A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
US8551072B2 (en) 2007-12-12 2013-10-08 Boston Scientific Scimed, Inc. Methods, devices and compositions for controlled drug delivery to injured myocardium
US8497303B2 (en) * 2008-01-18 2013-07-30 Dow Global Technologies Llc Method to enhance aqueous solubility of poorly soluble actives
WO2009143285A2 (en) 2008-05-21 2009-11-26 Amylin Pharmaceuticals, Inc. Exendins to lower cholestrol and triglycerides
WO2009148583A2 (en) * 2008-06-03 2009-12-10 Qlt Usa, Inc. Method for improvement of octreotide bioavailability
JP5951991B2 (ja) * 2008-08-12 2016-07-13 ノバルティス アーゲー 医薬組成物
EP2213307A1 (de) * 2009-02-03 2010-08-04 Novartis AG Injizierbare Depotformulierungen
MX2011003510A (es) 2008-10-02 2011-06-17 Mylan Inc Metodo para fabricar un laminado adhesivo de multiples capas.
US20100086597A1 (en) * 2008-10-06 2010-04-08 Oakwood Laboratories LLC Microspheres for the sustained release of octreotide with a low initial burst
JP2012524779A (ja) * 2009-04-23 2012-10-18 サステインド ナノ システムズ リミテッド ライアビリティ カンパニー 制御放出分配デバイス
US9498440B2 (en) 2009-05-22 2016-11-22 Inventia Healthcare Private Limited Extended release pharmaceutical compositions
WO2011005939A2 (en) 2009-07-09 2011-01-13 Mayo Foundation For Medical Education And Research Long acting atrial natriuretic peptide (la-anp) and methods for use thereof
US20120172456A1 (en) * 2009-09-10 2012-07-05 Little Steven R Engineered microparticles for macromolecule delivery
HUE035862T2 (en) * 2009-09-28 2018-05-28 Intarcia Therapeutics Inc Rapid establishment and/or termination of substantial steady-state drug delivery
EP2538956A4 (de) * 2010-02-22 2015-04-22 Edge Therapeutics Inc Verfahren und zusammensetzungen zur behandlung hämorrhagischer zustände des gehirns
KR101319420B1 (ko) * 2011-03-18 2013-10-17 한남대학교 산학협력단 서방형 방출이 가능한 수용성 양이온 약물 전달 시스템
KR20140059249A (ko) 2011-08-30 2014-05-15 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 나트륨이뇨 폴리펩티드
US9611305B2 (en) 2012-01-06 2017-04-04 Mayo Foundation For Medical Education And Research Treating cardiovascular or renal diseases
CN102552166A (zh) * 2012-01-09 2012-07-11 北京化工大学 一种溶菌酶/聚(α-氰基丙烯酸异丁酯)载药微球的制备方法
CN102552169B (zh) * 2012-02-17 2015-07-29 深圳市健元医药科技有限公司 一种醋酸阿肽地尔缓释微球制剂及其制备方法
TR201810930T4 (tr) 2012-05-18 2018-08-27 Genentech Inc Yüksek konsantrasyonlu monoklonal antikor formülasyonları.
US9040034B2 (en) 2013-04-09 2015-05-26 International Business Machines Corporation Vitamin functionalized gel-forming block copolymers for biomedical applications
JP6564369B2 (ja) 2013-12-09 2019-08-21 デュレクト コーポレイション 薬学的活性剤複合体、ポリマー複合体、ならびにこれらを伴う組成物及び方法
CN103720663B (zh) * 2014-01-08 2016-04-06 昆药集团股份有限公司 一种促卵泡激素缓释微球及其制备方法
DK3131549T3 (en) * 2014-07-09 2018-05-28 Pf Medicament PROCEDURE FOR TREATING MOVEMENT DISORDERS WITH BEFIRADOL
US11786469B2 (en) * 2014-07-22 2023-10-17 Cheolhee WON Silica nanoparticle composition for delivering bioactive material or protein such as a human proteasome
US9375478B1 (en) 2015-01-30 2016-06-28 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9687526B2 (en) 2015-01-30 2017-06-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744209B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9750785B2 (en) 2015-01-30 2017-09-05 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9925233B2 (en) 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
CA2988500A1 (en) * 2015-06-12 2016-12-15 Novo Nordisk A/S Selective pyy compounds and uses thereof
US11033520B2 (en) 2016-09-09 2021-06-15 Irisys, Inc. Liposomal anticancer compositions
WO2018089601A1 (en) 2016-11-09 2018-05-17 Mayo Foundation For Medical Education And Research Manp analogues
DE102016013737A1 (de) * 2016-11-17 2018-05-17 WindplusSonne GmbH Hexahydroxycyclohexanhexaphosphorsäureestersalze zur Behandlung von Kalzinose sowie diätische Lebensmittel mit Hexahydroxycyclohexanhexaphosphorsäureestersalzen als Zusatzstoffe
BR112020000504A2 (pt) 2017-07-11 2020-07-14 Sustained Nano Systems Llc esterilização por radiação de formas de dosagem de polímeros hipercomprimidos
AU2018300080B2 (en) 2017-07-11 2024-09-19 Sustained Nano Systems Llc Hypercompressed pharmaceutical formulations
KR102137786B1 (ko) * 2018-07-19 2020-07-24 주식회사 아울바이오 주사제용 미립구의 제조방법
FI3866765T3 (fi) * 2018-10-15 2024-04-18 Chong Kun Dang Pharmaceutical Corp Injektoitavia pitkävaikutteisia naltreksonimikropartikkelikoostumuksia
US11633416B1 (en) 2020-03-06 2023-04-25 Arcus Biosciences, Inc. Oral formulations of CD73 compounds
CN112661958B (zh) * 2020-12-09 2023-03-17 中山大学 一种基于肌醇和精氨酸的聚酯酰胺及其制备方法与应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US5059591B1 (en) * 1983-05-26 2000-04-25 Liposome Co Inc Drug preparations of reduced toxicity
US4578384A (en) * 1984-02-15 1986-03-25 The United States Of America As Represented By The Secretary Of The Army Polylactic-polyglycolic acids combined with an acidic phospholipid-lysozyme complex for healing osseous tissue
JP2551756B2 (ja) 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
US6312679B1 (en) 1986-08-18 2001-11-06 The Dow Chemical Company Dense star polymer conjugates as dyes
US4728202A (en) * 1987-01-14 1988-03-01 Emerson Electric Co. Shaft locking collar for bearing assemblies
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5538739A (en) 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
US5077049A (en) 1989-07-24 1991-12-31 Vipont Pharmaceutical, Inc. Biodegradable system for regenerating the periodontium
US5225205A (en) 1989-07-28 1993-07-06 Debiopharm S.A. Pharmaceutical composition in the form of microparticles
DE4004430A1 (de) 1990-02-09 1991-08-14 Schering Ag Aus polyaldehyden aufgebaute kontrastmittel
MY107937A (en) 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
JPH0426630A (ja) 1990-05-19 1992-01-29 Wakiyou Kagaku Kogyo Kk 水性製剤におけるリゾチーム塩の安定化方法
US5529914A (en) 1990-10-15 1996-06-25 The Board Of Regents The Univeristy Of Texas System Gels for encapsulation of biological materials
US5410016A (en) 1990-10-15 1995-04-25 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
SE469260B (sv) * 1992-02-25 1993-06-14 Perstorp Ab En farmaceutisk komposition med foerbaettrad biotillgaenglighet avseende inositolfosfat
EP0630234B1 (de) 1992-03-12 1997-06-11 Alkermes Controlled Therapeutics, Inc. Acth enthaltende mikrokugeln mit gesteuerter abgabe
ES2151541T3 (es) 1992-12-02 2001-01-01 Alkermes Inc Microesferas que contienen hormona del crecimiento de liberacion prolongada.
US5595760A (en) * 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
WO1996021440A1 (en) * 1995-01-09 1996-07-18 Alpha-Therapeutics, Inc. Methods for increasing the bioavailability of biological active agents
US5698213A (en) 1995-03-06 1997-12-16 Ethicon, Inc. Hydrogels of absorbable polyoxaesters
US6410044B1 (en) 1998-03-19 2002-06-25 Surmodics, Inc. Crosslinkable macromers
KR19990085365A (ko) * 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
US6461631B1 (en) 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
AU2001279118A1 (en) * 2000-08-01 2002-02-13 Gmp Companies, Inc. Ammonium salts of inositol hexaphosphate and uses thereof
IL140017A (en) * 2000-11-30 2009-09-22 Abraham J Domb Polyhedra
US6592899B2 (en) * 2001-10-03 2003-07-15 Macromed Incorporated PLA/PLGA oligomers combined with block copolymers for enhancing solubility of a drug in water
US7226624B2 (en) * 2002-07-24 2007-06-05 Rabinowitz Israel N Synergistic compositions from yeast-modified aqueous extracts from almond hulls
US20040097467A1 (en) * 2002-08-22 2004-05-20 Vijaya Juturu Arginine silicate inositol complex and use thereof
AU2003286472A1 (en) 2002-10-17 2004-05-04 Alkermes Controlled Therapeutics, Inc. Ii Microencapsulation and sustained release of biologically active polypeptides
US20040097419A1 (en) * 2002-11-19 2004-05-20 Holger Petersen Organic compounds
EP1786400B1 (de) * 2004-08-12 2009-03-11 Quest Pharmaceutical Services Pharmazeutische zusammensetzungen für die kontrollierte freigabe von biologischen wirkstoffen

Also Published As

Publication number Publication date
BRPI0514297A (pt) 2008-06-10
CY1109425T1 (el) 2014-08-13
AU2005271242A1 (en) 2006-02-16
NZ553149A (en) 2010-01-29
SI1786400T1 (sl) 2009-08-31
RU2007105872A (ru) 2008-09-20
KR20070043881A (ko) 2007-04-25
AU2005271242B9 (en) 2012-04-12
PT1786400E (pt) 2009-06-19
PL1786400T3 (pl) 2009-08-31
RU2390355C2 (ru) 2010-05-27
EP1786400B1 (de) 2009-03-11
WO2006017852A2 (en) 2006-02-16
AU2005271242B2 (en) 2011-09-15
HK1108638A1 (en) 2008-05-16
DE602005013244D1 (de) 2009-04-23
CA2576689A1 (en) 2006-02-16
EP1786400A4 (de) 2008-07-09
US7964219B2 (en) 2011-06-21
WO2006017852A3 (en) 2006-08-31
MX2007001760A (es) 2007-07-24
US20060034923A1 (en) 2006-02-16
JP2008511544A (ja) 2008-04-17
CA2576689C (en) 2012-10-09
EP1786400A2 (de) 2007-05-23
ES2323141T3 (es) 2009-07-07
CN101035512B (zh) 2012-01-18
DK1786400T3 (da) 2009-06-29
AU2005271242A2 (en) 2006-02-16
KR101231856B1 (ko) 2013-02-08
JP5053846B2 (ja) 2012-10-24
CN101035512A (zh) 2007-09-12

Similar Documents

Publication Publication Date Title
ATE424848T1 (de) Pharmazeutische zusammensetzungen für die kontrollierte freigabe von biologischen wirkstoffen
EA200800161A1 (ru) Новые фармацевтические композиции с модифицированным высвобождением и способ получения таких композиций
ATE396967T1 (de) (5-(2-hydroxy-4-chlorbenzoyl)valeriansäure und deren salze, und zusammensetzungen zur zuführung von wirkstoffen, die diese verbindungen enthalten
WO2007084460A3 (en) Pharmaceutical compositions with enhanced stability
ATE387430T1 (de) Verbindungen und zusammensetzungen zur abgabe aktiver wirkstoffe
BR0008590A (pt) Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
WO2004108162A3 (en) Controlled release pharmaceutical composition
GEP20125628B (en) Pharmaceutical compositions containing antagonist anti-cd40 antibody
IL291556B1 (en) Methods and compositions for cns delivery of arylsulfatase a
BRPI0508579A (pt) composto, composição farmacêutica, e, uso de um composto
UA110013C2 (uk) Застосування композиції для лікування шарко-марі-тута і пов'язаних з нею розладів
ATE413865T1 (de) Zusammensetzungen mit alphahydroxy-säureester zur wirkstofffreisetzung und anwendungsverfahren dafür
DE69819145D1 (de) Bioabbaubare mikropartikeln mit verzögerter wirkstofffreisetzung
EA200971132A1 (ru) Фармацевтическая композиция с пролонгированным высвобождением, приготовленная из микрочастиц
TW200740440A (en) Novel combinations of medicaments for the treatment of respiratory diseases containing long-acting beta-agonists and at least one additional active ingredient
MX2023012723A (es) Composiciones farmacéuticas y sistemas de administración de medicamentos intravítreos para el tratamiento de enfermedades oculares.
HK1123986A1 (en) Pharmaceutical formulation for the treatment of osteoarthritis containing clodronic acid and hyaluronic acid
DK1305057T3 (da) Mikropartikelformig biomaterialesammensætning af hyaluronsyre til medicinsk anvendelse
WO2006010084A3 (en) A system for delivering therapeutic agents into living cells and cell nuclei
ATE359800T1 (de) Pharmazeutische zusammensetzung mit einem zink/hyaluronat-komplex zur behandlung von multipler sklerose
CN103830162A (zh) 一种多西环素凝胶的制备方法
EA200701525A1 (ru) Фармацевтическая полимерная композиция для перорального введения тербуталина сульфата с контролируемым высвобождением
TNSN06335A1 (en) Novel stable oral risperidone solution
BRPI0510858A (pt) composição, composto e método para administrar um agente biologicamente ativo a um animal necessitando o mesmo

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1786400

Country of ref document: EP